The combination of radiation with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 therapies, has been shown to enhance the abscopal response by overcoming the immunosuppressive tumor microenvironment often present in metastatic disease [169,170,171,172]. Here, CTLA4 is linked to neoplasm.